Mitogen-activated protein kinase kinase
EC no.
IntEnzIntEnz view
ExPASyNiceZyme view
MetaCycmetabolic pathway
PDB structuresRCSB PDB PDBe PDBsum

Mitogen-activated protein kinase kinase (also known as MAP2K, MEK, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

MAP2K is classified as EC

There are seven genes:

The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways.[1] The acronym MEK derives from MAPK/ERK Kinase.[2]

Role in melanoma

MEK is a member of the MAPK signaling cascade that is activated in melanoma.[3] When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.

See also


  1. ^ Dérijard B, et al. (1995). "Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms". Science. 267 (5198): 682–5. doi:10.1126/science.7839144. PMID 7839144.
  2. ^ Dwivedi, Gaurav; Kemp, Melissa L. (February 15, 2012). "Systemic Redox Regulation of Cellular Information Processing". Antioxidants & Redox Signaling. 16: 374–80. doi:10.1089/ars.2011.4034. PMC 3279717. PMID 21939387.
  3. ^ Falchook, Gerald S.; Lewis, Karl D.; Infante, Jeffrey R.; Gordon, Michael S.; Vogelzang, Nicholas J.; DeMarini, Douglas J.; Fecher, Leslie A.; et al. (2012). "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial". The Lancet Oncology. 13 (8): 782–789. doi:10.1016/S1470-2045(12)70269-3. PMC 4109286. PMID 22805292.